Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
Why don’t good returns guarantee a 5-star rating?
Amy Arnott explains how Morningstar’s stock ratings work.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,932.40 | 64.90 | -0.72% |
| CAC 40 | 8,162.41 | 54.37 | -0.66% |
| DAX 40 | 25,811.95 | 233.42 | -0.90% |
| Dow JONES (US) | 50,205.93 | 553.49 | -1.09% |
| FTSE 100 | 10,561.08 | 128.79 | -1.20% |
| HKSE | 23,294.75 | 213.42 | -0.91% |
| NASDAQ | 24,394.54 | 66.15 | 0.27% |
| Nikkei 225 | 59,024.28 | 163.85 | 0.28% |
| NZX 50 Index | 14,264.29 | 42.67 | -0.30% |
| S&P 500 | 7,322.14 | 18.39 | -0.25% |
| S&P/ASX 200 | 8,821.80 | 61.40 | -0.69% |
| SSE Composite Index | 3,587.83 | 3.25 | 0.09% |